Tenderwize
Back to tender search

Open house Denosumab discount agreements

AOK Bayern - Die Gesundheitskasse·München, Germany·Deadline May 05, 2027 · 260 days left·Open·Supplies·Framework
Structured notice only
Original notice title

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Denosumab, ATC M05BX04

50/100

Opportunity Score

Needs reviewLow complexity
SuppliesFrameworkOpen
Why this score?

Opportunity

50 / 100

Complexity

20 / 100

Risk factors

No estimated value is provided, making it impossible to assess financial attractiveness.

Agreements automatically terminate if a formal discount contract for the same substance comes into effect. This could s...

Deep Portfolio Analysis

Deep Company Fit Analysis

Uses:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Overview

Moderate opportunity

Key Facts

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Jun 2027
  • Supply of Denosumab (active substance, ATC M05BX04) under discount agreements.
  • Non-exclusive framework agreement with no guarantee of volume or exclusivity.
Show full summary

This is an open house model (non-exclusive) for discount agreements on the drug Denosumab (ATC M05BX04) with AOK Bayern. It is not a standard procurement procedure; any eligible pharmaceutical company can join under identical non-negotiable terms. Agreements run from 01/07/2025 to 30/06/2027, with rolling entry until 05/05/2027. No estimated value provided. Submission requires a signed contract and self-declaration of reliability, either in paper form (two copies) or electronically with a qualified electronic signature. Eligibility is limited to pharmaceutical companies.

Risks

No estimated value is provided, making it impossible to assess financial attractiveness.

Agreements automatically terminate if a formal discount contract for the same substance comes into effect. This could s...

Analysis may be incomplete

Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.

Key Requirements

Technical

  • Proof of legal representation (handelsregister extract or power of attorney).

Eligibility

  • Eligible participants: only pharmaceutical companies.

Administrative

  • Submission of a signed contract and a signed self-declaration of reliability.

Requirements may be incomplete.

Award Criteria

Lot 1

No award criteria; all eligible companies are accepted.

Buyer

Location

München, DEU

Website

www.aok.de

Buyer profile

Open profile

Identifier

DE811695320

Activity

Health

Lots (1)

LOT-0001

Open house Denosumab discount agreements

Non-exclusive discount agreements for Denosumab (ATC M05BX04) to be concluded with all eligible pharmaceutical companies under identical terms. Place of performance: Bavaria, Germany (DE212). Framework agreement type.

SuppliesFrameworkEU fundedElectronic submission

Location

DE212, Germany

Duration

Jun 2025 - Jun 2027

Category

Pharmaceutical products

Award Criteria

No award criteria; all eligible companies are accepted.

Deadline

Deadline May 05, 2027

Procurement Details

Publication date
15 May 2025
Languages
German

Reference metadata

Legal basis
32014L0024

Reference IDs

Tender ID
317417-2025

Documents (2)

Similar tenders